Evidence map›Paper›PMID 42671253›Full record

ArticleJournal of virology2026

BKV activates the interferon-β response in primary and immortalized microvascular endothelial cells late in the infectious cycle, resulting in persistence.

Lindsay C Colgan, Ping An, Paul G Cantalupo, Wenshan Zheng, Abigail R Velasquez, Alexis M Duray, Maria Teresa Sáenz Robles, David Weitz, James M Pipas

Abstract read
In one paragraph

Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Lindsay C ColganDepartment of Biological Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Ping AnDepartment of Biological Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Paul G CantalupoDepartment of Biomedical Informatics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Wenshan ZhengJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts, USA.
Abigail R VelasquezDepartment of Biological Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Alexis M DurayDepartment of Biological Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Maria Teresa Sáenz RoblesDepartment of Biological Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
David WeitzJohn A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, Massachusetts, USA.ORCID 0000-0001-6678-5208
James M PipasDepartment of Biological Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID 0000-0003-1253-300X

Funding

Manipulation of innate immunity by Polyomavirus T antigensR01AI153156 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PIPAS, JAMES M · 2020 to 2024
$2.0M
High-Throughput Computing for Genomics and Bioinformatics ResearchS10OD028483 · OD · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEE, ADRIAN V · 2021 to 2021
$574k
NIAID NIH HHS R01 AI153156NIH HHS RO1 AI153156, S10OD028483NIH HHS S10 OD028483
6 · The paper itself

Abstract

Our previous studies have shown that inoculation of primary endothelial cells with BKV results in a long-term persistent infection, with inoculated cultures surviving up to 60 days while producing low levels of infectious viral progeny. Unlike the permissive renal proximal tubule cells, infected endothelial cells activate innate immunity pathways in response to BKV infection. We hypothesized that the innate immune response limits BKV infection, resulting in persistence. In this report, we show that activation of innate immune pathways is not triggered by incoming virus particles but rather occurs at a late stage of the infectious cycle, when viral DNA replication, high levels of late viral transcription, and progeny virion assembly are occurring. Single-cell transcriptomic data indicate that this response varies across the infected cell population, with some cells showing little or no innate immune response, while others appear to be highly activated. Bulk RNA-seq experiments show that the addition of interferon-β to endothelial cells results in the upregulation of a subset of known interferon-stimulated genes (ISGs), as well as many other genes not known to be associated with the interferon response. Finally, we show that the addition of interferon-β blocks BKV infection, so long as it is added prior to or soon after inoculation. These results lead to a model in which BKV infection of endothelial cells results in interferon production and ISG induction that restrict subsequent rounds of infection and lead to a persistent state. IMPORTANCE: BKV infects nearly every human on Earth, and the infection persists throughout life. The cell types where the virus persists remain a mystery, as do the state of the viral genome during persistence, as well as the mechanisms that limit productive infection and maintain persistence. While BKV is known to replicate robustly in renal proximal tubule cells during disease, it is not clear whether the virus persists in these cells. The proximal tubules are located in close proximity to endothelial cells, raising the possibility that BKV persistence occurs in the endothelia, and virus particles from infected endothelia potentially seed infections in the neighboring tubular epithelia during times of cellular stress or immunosuppression. The development of cell culture systems to study the interactions between innate immunity, virus production, and persistence is needed to advance the development of anti-viral strategies.

Indexed as

BK VirusEndothelial CellsInterferon-betaPolyomavirus InfectionsCells, CulturedHumansImmunity, InnatePersistent InfectionVirus ReplicationInterferon-betaendothelial cellsinnate immunitypolyomavirus BKV

Identifiers

PMID42671253
PMCPMC13595990

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.